e-Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2021

Understanding the effects of chemotherapy on sleep disturbance in lung cancer patients: a systematic review (#333)

Andrew T Jeklin 1 2 , Rishi Kumarahuru 1 , Muhammad Amalgeer 1 3 , Rob Stirling 1 4 , Jordan Maccora 5 , Dion Paul 1 , Josh Wiley 5
  1. Department of Medicine, Monash University , Melbourne, Victoria , Australia
  2. Australian Institute of Tropical Health & Medicine, James Cook University, Cairns , Queensland, Australia
  3. Department of Medical Oncology, Monash Health, Melbourne, Victoria , Australia
  4. Department of Respiratory Medicine, Alfred Health, Melbourne, Victoria , Australia
  5. Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria , Australia

Introduction:

 

Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. Despite therapeutic advances, systemic chemotherapy remains a standard of care for majority of advanced stage disease. Sleep disturbance is an unrecognized and commonly unaddressed problem in lung cancer, possibly potentiated by chemotherapy. A detailed understanding may assist in the development of optimal interventions to improve quality of life. The aims were to study sleep prior to/without treatment and to investigate the impact of chemotherapy on sleep in patients with lung cancer.

 

Methods:

 

In compliance with PRISMA guidelines, we performed a literature search of 3558 articles between 1946 and 2020. Articles that investigated the impact of chemotherapy compared with no treatment (baseline), on sleep disturbance were included. Articles that reported sleep at baseline, without treatment, were also included for comparative analysis. The main outcome measure was the insomnia subscale score from the Quality of Life Questionnaire for Cancer Patients (QLQ-C30) at baseline, during and after chemotherapy.  The authenticity of the results was measured using sensitivity analysis. 

 

Results:

 

A total of 14 studies were included in the meta-analysis. Sleep disturbance prior to treatment in lung cancer patients, as measured on the QLQ-C30 Insomnia measure (0-100;higher worse), was 33.73 (CI: 32.52 – 34.95). During chemotherapy, measured during cycles 3 and 4 (weeks 9-12), the QLQ-C30 Insomnia score was 21.96 (CI: 21.96 – 24.60) in lung cancer patients. The mean difference was (CI). There was significant heterogeneity chi2=, I2= ‘Final Analysis will be presented at the meeting”

 

 

Conclusion:

 Lung cancer patients who received chemotherapy reported lower levels of sleep disturbance than those who did not receive treatment. It remains unclear the exact mechanisms responsible for these findings but it is evident the need for longer prospective randomized control studies to examine the relationship of chemotherapy and sleep in lung cancer patients.